Bayer HealthCare’s Consumer Care division announced today the introduction of Bayer® Advanced Aspirin, the next generation of aspirin for pain relief. Using the patent-pending Pro-Release™ Technology, Bayer Advanced Aspirin is clinically proven to relieve tough pain twice as fast as previous Bayer® Aspirin tablets.
With the introduction of aspirin in 1899, Bayer offered one of the first widely accessible analgesics, or pain relievers, to consumers. Today, Bayer's overall global Aspirin business continues to grow, and had double-digit, year-on-year sales growth in Q1 2011. Yet, while Bayer continues to be a leader in the category, for many U.S. consumers, Bayer Aspirin is primarily synonymous with cardiovascular use. Now, through a combination of technological innovation and rich analgesic heritage, Bayer is introducing a new standard in aspirin for tough pain relief with Bayer Advanced Aspirin.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bayer/50414/
For juicy, tender and flavorful pork, it might be time to toss out Grandma’s advice. Announced today, new U.S. Department of Agriculture (USDA) guidelines confirm that 145 degrees Fahrenheit as measured on a food thermometer, followed by a three-minute rest time, is a safe final internal cooking temperature for pork.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/pork/50354/
Today, Target Corp.® (NYSE:TGT) announced 42 new schools from across the country that will receive a new library as part of the 2011 Target School Library Makeover program. Education experts and advocates such as Alma Powell of the America’s Promise Alliance and Sir Ken Robinson, along with elected officials including Congressman John Kline, Chairman of the Education and the Workforce Committee and Congressman Gene Green (TX-29), were invited to celebrate this announcement with the principals at the Library of Congress. Additionally, principals from among the 42 elementary schools participated in a Principal Summit, led by Ralph Smith of The Annie E. Casey Foundation. The summit was designed to inspire school leaders, provide best practices for cultivating reading skills by using their new libraries, and explore how educators approach literacy strategies.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/target/50372/
VISTAKON®, Division of Johnson & Johnson Vision Care, Inc., and makers of ACUVUE® Brand Contact Lenses, today announced the “ACUVUE® 1·DAY Contest,” which will bring five winners to Los Angeles to meet and be mentored by one of five top teen icons, including musician Joe Jonas, all-American actress Meaghan Martin, singing phenom Charice, world champion runner Allyson Felix and actor Sterling Knight.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/acuvue/50390/
Shake Weight, the nation’s most talked about, best-selling and most parodied fitness craze, is the centerpiece of a newly-released independent study that proves the world-famous arm-sculpting device is no laughing matter.
FitnessIQ, marketers of the Shake Weight, today disclosed findings of a scientific study conducted by Dr. Jeffrey M. Willardson, an Associate Biomechanics Professor at Eastern Illinois University (EIU). The study evaluated the effects of incorporating a six-minute Shake Weight routine in the warm-up sessions of three Division I collegiate athletic teams, measuring the device’s impact on performance. The study demonstrated that athletes across all three sports, including baseball, volleyball and soccer, improved reaction time by 10% to 17%.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/fitnessiq/50394/
Kelley Blue Book today announces a redesign of its top-rated website www.kbb.com, revolutionizing the way consumers research new car and used car information. The site’s new task-based navigation shifts the standard online car-research paradigm, delivering the information visitors need in a faster, more engaging manner.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/kbb/47373/
SoBe® gets it. Life is more exciting -- and more fun -- when you try new things, whether it’s a new flavor (Yumberry Pomegranate anyone?) or a new experience (let’s say, milking a fake cow). Today, SoBe and a team of adventure-seeking celebrities are making it possible for fans to “Try Everything” in New York City’s Madison Square Park from 10 am to 4 pm.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/sobe/50416/
SoBe® gets it. Life is more exciting -- and more fun -- when you try new things, whether it’s a new flavor (Yumberry Pomegranate anyone?) or a new experience (let’s say, milking a fake cow). Today, SoBe and a team of adventure-seeking celebrities are making it possible for fans to “Try Everything” in New York City’s Madison Square Park from 10 am to 4 pm.
To view Multimedia News release, go to http://multivu.prnewswire.com/mnr/sobe/50416/
Travis Air Force Base squadron members took to the sky at Six Flags Discovery Kingdom today, as the first “flyers” to experience the park’s newest thrill ride, SkyScreamer. SkyScreamer, which opens to the public on Friday, May 27, is the latest sensation in tower rides, and takes the concept of spinning round and round to a new level of thrills. The lofty attraction joins the park’s unique array of rides, shows and interactive animal experiences.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/sixflags/49942/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
SoBe® gets it. Life is more exciting -- and more fun -- when you try new things, whether it’s a new flavor (Yumberry Pomegranate anyone?) or a new experience (let’s say, milking a fake cow). Today, SoBe and a team of adventure-seeking celebrities are making it possible for fans to “Try Everything” in New York City’s Madison Square Park from 10 am to 4 pm.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/sobe/50416/
SoBe® gets it. Life is more exciting -- and more fun -- when you try new things, whether it’s a new flavor (Yumberry Pomegranate anyone?) or a new experience (let’s say, milking a fake cow). Today, SoBe and a team of adventure-seeking celebrities are making it possible for fans to “Try Everything” in New York City’s Madison Square Park from 10 am to 4 pm.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/sobe/50416/
